Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Drugs acting on the gastrointestinal system and metabolism
Bevenopran
Другие языки:

    Bevenopran

    Подписчиков: 0, рейтинг: 0
    Bevenopran
    Bevenopran.svg
    Legal status
    Legal status
    • Investigational
    Identifiers
    • 5-[2-Methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C20H26N4O4
    Molar mass 386.452 g·mol−1
    3D model (JSmol)
    • COC1=C(C=CC(=C1)CNCCC2CCOCC2)OC3=NC=C(N=C3)C(=O)N
    • InChI=1S/C20H26N4O4/c1-26-18-10-15(11-22-7-4-14-5-8-27-9-6-14)2-3-17(18)28-19-13-23-16(12-24-19)20(21)25/h2-3,10,12-14,22H,4-9,11H2,1H3,(H2,21,25)
    • Key:ZGCYVRNZWGUXNQ-UHFFFAOYSA-N

    Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued.

    See also




    Новое сообщение